Comparative Effectiveness of Palbociclib Plus Aromatase Inhibitor Versus Fulvestrant Alone as Initial Endocrine Therapy for HR+/HER2- Advanced Breast Cancer in Chinese Clinical Practice: a Real-world Study
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms CAPACITY
- 24 Apr 2022 Status changed from not yet recruiting to recruiting.
- 19 Aug 2021 New trial record